Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid‐related health problems: a population‐based retrospective cohort study

Aims Although opioid‐related harms have reached new heights across North America, the size of the gap in opioid agonist therapy (OAT) delivery for opioid‐related health problems is unknown in most jurisdictions. This study sought to characterize the gap in OAT treatment using a cascade of care frame...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Addiction (Abingdon, England) England), 2023-04, Vol.118 (4), p.686-697
Hauptverfasser:	Paul, Lauren A., Bayoumi, Ahmed M., Chen, Cynthia, Kocovska, Elena, Smith, Brendan T., Raboud, Janet M., Gomes, Tara, Kendall, Claire, Rosella, Laura C., Bitonti‐Bengert, Lisa, Rush, Brian, Yu, Melissa, Spithoff, Sheryl, Crichlow, Frank, Wright, Amy, Watford, Jase, Besharah, Jes, Munro, Charlotte, Taha, Sheena, Nosyk, Bohdan, Strike, Carol, Manson, Heather, Kahan, Meldon, Leece, Pamela
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonist Agonists Analgesics Analgesics, Opioid - therapeutic use Buprenorphine Buprenorphine - therapeutic use Clinical outcomes Cohort analysis Death Death & dying Drug addiction Gender differences Health problems Health status Humans Male Males Men Mental health Methadone Methadone - therapeutic use Naloxone Narcotics Neighborhoods OAT Older people Ontario - epidemiology Opiate Substitution Treatment - methods opioid Opioid-Related Disorders - therapy Opioids Population studies Population-based studies Retention Retrospective Studies Rural areas Rural communities substance use treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Although opioid‐related harms have reached new heights across North America, the size of the gap in opioid agonist therapy (OAT) delivery for opioid‐related health problems is unknown in most jurisdictions. This study sought to characterize the gap in OAT treatment using a cascade of care framework, and determine factors associated with engagement and retention in treatment. Design A population‐based retrospective cohort study. Setting Ontario, Canada. Participants Individuals who sought medical care for opioid‐related health problems or died from an opioid‐related cause between 2005 and 2019. Measurements Monthly treatment status for buprenorphine/naloxone or methadone OAT between 2013 and 2019 (i.e. ‘off OAT’, ‘retained on OAT
ISSN:	0965-2140 1360-0443
DOI:	10.1111/add.16096